There is “substantial doubt” that Impel Pharmaceuticals can continue, and the biotech, which has one migraine nasal spray treatment, is considering bankruptcy or selling off its assets, according to SEC filings.
Impel reported product revenue of $6.6 million for the second quarter — a jump from…
Click here to view original post
